National Medical Products Administration has opened a supply, manufacturing and research site in Zhenjiang and plans a commercial-scale version in Nanjing . The company wants a prominent place in Zhenjiang ’s biologics, cell and gene-based treatments market. It said the commercial facility would be the first and largest such site in China which researched and developed gene and cell therapies and antibody drugs. With Western drugmakers taking new-generation meds to China, GenScript Biotech is looking to be a key player in China’s CDMO market for biologics and cell and gene-based treatments. The larger site will also cover plasmid and virus manufacture.
National Medical Products Administration has opened a supply, manufacturing and research site in Zhenjiang and plans a commercial-scale version in Nanjing . The company wants a prominent place in Zhenjiang ’s biologics, cell and gene-based treatments market. It said the commercial facility would be the first and largest such site in China which researched and developed gene and cell therapies and antibody drugs. The larger site will also cover plasmid and virus manufacture.